Task 148123
Retatrutide (10mg)
99.734% / 99.751% purity reported
Evidence cluster
Metabolic & Endocrine Signalling
Compound records and comparative research involving incretin, glucagon and growth-hormone-releasing pathways, with human trials kept separate from batch-quality evidence and unapproved-product claims.
Research frame
Questions this cluster is built to answer
- 01Which receptor system does each compound target?
- 02Was the evidence generated in cells, animals, healthy volunteers or a defined patient population?
- 03Does a medicine trial apply to the physical research material being assessed?
Compound evidence records
Evidence dossier
Retatrutide
An evidence map for retatrutide covering receptor pharmacology, the published phase 2 programme, current uncertainty and identity-testing questions.
Open recordEvidence dossier
Tirzepatide
A source-led guide to tirzepatide identity, dual-receptor pharmacology, human trial evidence and the limits of applying medicine data to research materials.
Open recordEvidence dossier
CJC-1295
A nomenclature-first guide that separates CJC-1295 with DAC from shorter non-DAC material and maps the limited human and analytical evidence.
Open recordEvidence dossier
Tesamorelin
An indication-specific evidence guide to tesamorelin, separating established pharmaceutical trials from unrelated catalogue or body-composition claims.
Open recordEvidence dossier
Ipamorelin
A guide to Ipamorelin's early pharmacology and human PK/PD work, with clear separation from CJC-1295 and from performance claims.
Open recordMethods and connected analysis
Research Insights
Semaglutide, Tirzepatide and Retatrutide: Receptors and Study Context
Compare the receptor targets and selected primary studies while keeping formulation, population and trial design attached to each finding.
Research Insights
GLP-1 Research, Visceral Fat and Inflammation: Separate the Endpoints
Read metabolic studies without confusing MRI fat measurements, inflammatory biomarkers and clinical outcomes. Includes a primary-study example.
Research Insights
Retatrutide Research Costs in Australia: Comparing Vials and Quotes
Compare exact presentations, disclosed discounts, shipping and documentation when preparing an Australian laboratory procurement estimate.
Research Insights
Peptide Weight-Loss Research: How to Compare Evidence
An evidence-reading guide to semaglutide, tirzepatide and retatrutide studies, explaining why separate trials cannot produce a simple supplier ranking.
Document navigation
Published analytical records in this topic
Each record transcribes a published laboratory document and states its limits. A document is not treated as proof of the current inventory lot.
Task 134889
Retatrutide (20mg)
99.867% purity reported
Task 85117
Tirzepatide (20mg)
99.505% purity reported
Task 97935
CJC-1295 (no DAC) (10mg)
99.488% / 99.475% purity reported
Task 66682
CJC-1295 (no DAC) + Ipamorelin (10mg)
2 composition results published
Task 80925
Retatrutide (30mg)
99.676% purity reported
Task 123368
Tesamorelin (10mg)
99.796% purity reported
Catalogue context
Related public catalogue collections
These links organise public laboratory catalogue records by research subject. Catalogue availability is not evidence for a therapeutic outcome.